First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Published:2016-07 Issue:7 Volume:17 Page:928-942
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Eichhorst Barbara,Fink Anna-Maria,Bahlo Jasmin,Busch Raymonde,Kovacs Gabor,Maurer Christian,Lange Elisabeth,Köppler Hubert,Kiehl Michael,Sökler Martin,Schlag Rudolf,Vehling-Kaiser Ursula,Köchling Georg,Plöger Christoph,Gregor Michael,Plesner Torben,Trneny Marek,Fischer Kirsten,Döhner Harmut,Kneba Michael,Wendtner Clemens-Martin,Klapper Wolfram,Kreuzer Karl-Anton,Stilgenbauer Stephan,Böttcher Sebastian,Hallek Michael

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Chronic lymphocytic leukemia in young (;Parikh;Haematologica,2014

2. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

3. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia;Thompson;Blood,2016

4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

5. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial;Hallek;Lancet,2010

Cited by 513 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia;Annals of Hematology;2024-02-03

3. JAK/STAT in leukemia: a clinical update;Molecular Cancer;2024-01-26

4. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

5. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease;Current Oncology Reports;2024-01-04